The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-chloro-N-(4-(4-(1-cyclopropylpiperidin-4-yloxy)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-2-fluorobenzenesulfonamide ID: ALA5093302
PubChem CID: 86270186
Max Phase: Preclinical
Molecular Formula: C26H26ClFN6O3S
Molecular Weight: 557.05
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)nc(OC3CCN(C4CC4)CC3)c12
Standard InChI: InChI=1S/C26H26ClFN6O3S/c1-15-23-25(32-31-15)29-24(30-26(23)37-20-10-12-34(13-11-20)19-7-8-19)16-2-5-18(6-3-16)33-38(35,36)22-14-17(27)4-9-21(22)28/h2-6,9,14,19-20,33H,7-8,10-13H2,1H3,(H,29,30,31,32)
Standard InChI Key: YJCUOPUYDCNYOE-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 43 0 0 0 0 0 0 0 0999 V2000
30.1421 -6.8014 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
30.5568 -7.5146 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
30.9671 -6.7990 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.9817 -6.6937 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9806 -7.5169 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6918 -7.9278 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4048 -7.5165 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4019 -6.6900 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6900 -6.2829 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2692 -7.9269 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.8472 -7.9258 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1373 -7.5125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.4265 -7.9218 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.4254 -8.7436 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1411 -9.1545 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.8489 -8.7429 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1393 -6.6915 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
34.1084 -6.2781 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.8419 -6.7209 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.8099 -5.0458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.1039 -5.4606 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.5274 -5.4533 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.5304 -6.2731 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.3109 -6.5237 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.7904 -5.8587 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.3062 -5.1973 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1433 -9.9755 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
34.8040 -4.2248 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
34.0900 -3.8195 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5571 -4.4156 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.0866 -3.0012 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3767 -2.5961 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6663 -3.0083 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.6703 -3.8301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3847 -4.2398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9538 -2.6002 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5440 -1.8938 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.1361 -2.6063 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
5 10 1 0
10 2 1 0
2 11 1 0
11 12 2 0
12 13 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 11 1 0
12 17 1 0
18 19 2 0
19 23 1 0
22 20 1 0
20 21 2 0
21 18 1 0
8 18 1 0
22 23 2 0
23 24 1 0
24 25 1 0
25 26 2 0
26 22 1 0
15 27 1 0
20 28 1 0
28 29 1 0
26 30 1 0
29 31 1 0
29 35 1 0
31 32 1 0
32 33 1 0
33 34 1 0
34 35 1 0
33 36 1 0
37 36 1 0
38 37 1 0
36 38 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 557.05Molecular Weight (Monoisotopic): 556.1460AlogP: 4.93#Rotatable Bonds: 7Polar Surface Area: 113.10Molecular Species: ACIDHBA: 7HBD: 2#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: 6.48CX Basic pKa: 8.46CX LogP: 2.94CX LogD: 3.02Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.33Np Likeness Score: -1.88
References 1. Halland N, Schmidt F, Weiss T, Li Z, Czech J, Saas J, Ding-Pfennigdorff D, Dreyer MK, Strübing C, Nazare M.. (2022) Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of Osteoarthritis., 65 (2.0): [PMID:34931844 ] [10.1021/acs.jmedchem.1c01601 ]